Why the study?
The incidence of hypercholesterolemia and its relationship with clinical course in CLL patients were not well characterized.
Does statin use prolong time to first treatment in patients with chronic lymphocytic leukemia?
Cohort (n=231)
Does statin use prolong time to first treatment in patients with chronic lymphocytic leukemia?
Statin use is associated with a prolonged time to first treatment in patients with chronic lymphocytic leukemia, suggesting that cholesterol-lowering therapy may favorably impact the disease course.
Answers are grounded in this paper and cite their sources.
Hypercholesterolemia may influence TFT in CLL; leaves open whether statins alter disease course.
The incidence of hypercholesterolemia and its possible relationship with clinical course were determined by reviewing the records of 231 consecutive patients presenting to a specialized Chronic Lymphocytic Leukemia (CLL) clinic. Evidence for elevated cholesterol was found in up to 174/231 patients (75%) based on existing use of statins (107 patients) or non-fasting low-density lipoprotein cholesterol levels greater than 2.5 mM. Excluding patients with 17p deletions, time to first treatment (TFT) was prolonged if patients were taking cholesterol-lowering statins (57.5 (IQR = 32, 77) vs 36 (IQR = 11, 100) months, p < 0.02). If patients were prescribed statins after being diagnosed with CLL, TFT was longer than if they were taking statins before the diagnosis. These observations suggest there is a high incidence of hypercholesterolemia in CLL patients and cholesterol-lowering may impact the disease course.
No takes yet. Share an insight, caveat, or question.
Chow et al. (2015) conducted a cohort in Chronic Lymphocytic Leukemia (CLL) (n=231). Cholesterol-lowering statins vs. Not taking statins was evaluated on Time to first treatment (TFT) excluding patients with 17p deletions (p=<0.02).
Synapse has enriched 10 related papers. Consider them for comparative context: